Related Experiment Video
Updated: Jan 10, 2026
09:25
The Treadmill Fatigue Test: A Simple, High-throughput Assay of Fatigue-like Behavior for the Mouse
Published on: May 31, 2016
19.9K
Methylphenidate for Depression in Advanced Cancer: Exploratory Meta-Analysis of Randomized Trials.
Bruno Almeida Costa1, Victor Almeida Costa2, Debora Oliveira3
1Division of Cancer Medicine (B.A.C.), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Journal of Pain and Symptom Management
|November 25, 2025
Summary
Methylphenidate (MPH) offers rapid relief for depression in advanced cancer patients, showing significant symptom improvement and increased remission rates with a good safety profile. Further research is needed to confirm these findings.
Area of Science:
- Oncology
- Psychiatry
- Pharmacology
Background:
- Depression is common and undertreated in advanced cancer patients.
- Methylphenidate (MPH) is a potential rapid-acting treatment, but evidence is limited.
Purpose of the Study:
- To assess the efficacy and safety of MPH for managing depression in adults with advanced malignancies.
Main Methods:
- Systematic review and meta-analysis of double-blind, placebo-controlled randomized trials.
- Searched PubMed, Embase, and CENTRAL databases.
- Primary outcome: change in depressive scores at 2 weeks (SMD); Secondary outcomes: depression remission (RR, RD) and adverse events.
Main Results:
- MPH significantly reduced depressive symptom severity (SMD -0.81, P < 0.001).
- MPH increased the absolute probability of depression remission (RD 0.22, P < 0.001; NNT ≈ 5).
- Treatment-emergent adverse events were similar between MPH and placebo groups.
Conclusions:
- MPH may rapidly improve depressive symptoms in advanced cancer patients with a favorable safety profile.
- Further large-scale trials are necessary to confirm efficacy and identify optimal patient candidates due to small sample sizes and short follow-up.
Related Concept Videos
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
797
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
797
01:23Antidepressant Drugs: MAOIs and Other Agents
776
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
776
01:21Cancer Survival Analysis
633
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
633
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
527
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
527
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
578
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
578
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K